Abstract | BACKGROUND:
Antiphospholipid syndrome (APS) is a disorder of recurrent venous or arterial thrombosis, pregnancy losses, and thrombocytopenia. Recurrent thrombosis has particularly adverse effects on patients prognosis. The factors that influence recurrence and management techniques that prevent these events remain controversial. To add further insight regarding predisposing factors and the prevention of thrombotic recurrence, 61 well-characterized patients with APS were followed up for a median time of 77 months. METHODS: RESULTS: There was no difference between patients with primary and secondary APS with respect to recurrent arterial (55% vs 38%, respectively) or recurrent venous (47% vs 50%, respectively) thrombotic events. In all patients with APS, white race (P = .02) was associated with recurrent arterial events. Venous thrombosis occurred during pregnancy or in the postpartum period in 16 (30%) of 53 women and in 8 women taking oral contraceptives. Recurrent arterial and venous thromboses were significantly decreased with prophylactic warfarin use when compared with prednisone use or no treatment. Recurrences were infrequent in patients with prothrombin ratios of 1.5 to 2.0. CONCLUSIONS:
|
Authors | S Krnic-Barrie, C R O'Connor, S W Looney, S S Pierangeli, E N Harris |
Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 157
Issue 18
Pg. 2101-8
(Oct 13 1997)
ISSN: 0003-9926 [Print] United States |
PMID | 9382667
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anticoagulants
- Warfarin
- Aspirin
|
Topics |
- Adult
- Anticoagulants
(therapeutic use)
- Antiphospholipid Syndrome
(complications, drug therapy)
- Aspirin
(therapeutic use)
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Recurrence
- Retrospective Studies
- Risk Factors
- Thrombosis
(immunology, prevention & control)
- Treatment Outcome
- Warfarin
(therapeutic use)
|